“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The Raf/Mek/Erk signaling pathway, activated downstream of Ras primarily to promote proliferation, represents the best studied of the evolutionary conserved MAPK cascades. The investigation of the pathway has continued unabated since its discovery roughly 30 years ago. In the last decade, however, the identification of unexpected in vivo functions of pathway components, as well as the discovery of Raf mutations in human cancer, the ensuing quest for inhibitors, and the efforts to understand their mechanism of action, have boosted interest tremendously. From this large body of work, protein–protein interaction has emerged as a recurrent, crucial theme. This review focuses on the role of protein complexes in the regulation of the Raf/Mek/Erk pathway and in its cross‐talk with other signaling cascades. Mapping these interactions and finding a way of exploiting them for therapeutic purposes is one of the challenges of future molecule‐targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“New generation ATP-competitive Raf inhibitors, such as the clinically approved vemurafenib (PLX4032) [93–97] and dabrafenib (GSK2118436) [96,98], have improved selectivity for mutant B-RafV600E (Table 1), resulting in high response rates and increased progression-free and overall survival in patients with BRAF mutant…”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
ROCKs: multifunctional kinases in cell behaviour
Riento, K., & Ridley, A. J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1128 · Cited by 1,941
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“A prominent one is pathway reactivation by upstream components, such as receptor tyrosine kinases (RTKs; EGFR, PDGFRb, IGF-1R, MET through HGF secretion by the tumor microenvironment) [114–118].”
BackgroundCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“B-RafV600E amplification [126], expression of B-RafV600E splice variants promoting Ras-independent dimerization (p61BRafV600E) [30], C-Raf overexpression [116,122,127], Raf isoform signal switching [116] and increased expression of the alternative Mek kinase COT (Tpl2) [128] have all been reported and connected”
BackgroundWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 2×
“A prominent one is pathway reactivation by upstream components, such as receptor tyrosine kinases (RTKs; EGFR, PDGFRb, IGF-1R, MET through HGF secretion by the tumor microenvironment) [114–118].”
BackgroundReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Defective Thymocyte Maturation in p44 MAP Kinase (Erk 1) Knockout Mice
Pagès, G., Guérin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., & Pouysségur, J. (1999) · Science · doi:10.1126/science.286.5443.1374 · Cited by 654
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
Mazzucchelli, C., Vantaggiato, C., Ciamei, A., Fasano, S., Pakhotin, P., Krezel, W., Welzl, H., Wolfer, D. P., Pagès, G., Valverde, O., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00716-x · Cited by 456 · cited 1×
“In contrast, Erk1 knockout mice show only some minor defects in T-cell development, decreased adiposity and facilitated learning [45–47].”
BackgroundPI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426 · cited 5×
“As a positive regulator, PP2A associates with C-Raf [65–69] and Ksr1 [68] and dephosphorylates negative regulatory sites on both proteins, allowing their recruitment to the membrane [66–69] and leading to Mek and Erk activation [65–68].”
BackgroundInfluentialAn essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development
Saba‐El‐Leil, M. K., Vella, F. D. J., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S., & Meloche, S. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor939 · Cited by 366
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · cited 1×
“strated in K-Ras-driven lung cancer models, but its molecular basis is currently unclear [89,90].”
BackgroundOry, S., Zhou, M., Conrads, T. P., Veenstra, T. D., & Morrison, D. K. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00535-9 · Cited by 296 · cited 3×
“As a positive regulator, PP2A associates with C-Raf [65–69] and Ksr1 [68] and dephosphorylates negative regulatory sites on both proteins, allowing their recruitment to the membrane [66–69] and leading to Mek and Erk activation [65–68].”
BackgroundThe discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289
Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits
Silverstein, A. M., Barrow, C. A., Davis, A. J., & Mumby, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072071699 · Cited by 276
Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., & McCormick, F. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.027 · Cited by 215 · cited 1×
“A similar role in C-Raf activation has been described for the catalytic subunit of PP1C, which associates with C-Raf in Ras- and growth factor-stimulated cells [70].”
BackgroundIshii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Kins, S., Kurosinski, P., Nitsch, R. M., & Götz, J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63444-x · Cited by 155
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149
Self-citationAdams, D. G., Coffee, R. L., Zhang, H., Pelech, S., Strack, S., & Wadzinski, B. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502464200 · Cited by 133 · cited 1×
“As a positive regulator, PP2A associates with C-Raf [65–69] and Ksr1 [68] and dephosphorylates negative regulatory sites on both proteins, allowing their recruitment to the membrane [66–69] and leading to Mek and Erk activation [65–68].”
Background
Cited by
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Short and tall stature: a new paradigm emerges
Baron, J., Sävendahl, L., De Luca, F., Dauber, A., Phillip, M., Wit, J. M., & Nilsson, O. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.165 · Cited by 314
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 284
Scanu, T., Spaapen, R. M., Bakker, J. M., Pratap, C. B., Wu, L.-E., Hofland, I., Broeks, A., Shukla, V. K., Kumar, M., Janssen, H., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.05.002 · Cited by 266
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Metadata
- Authors
- Cseh, B., Doma, E., & Baccarini, M.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2014-06-14
- Volume
- 588
- Issue
- 15
- Pages
- 2398-2406
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2091271116
- Cited by
- 105
- References
- 28
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.